Recent Conference Coverage
Recent trial data indicate that axillary lymph node dissection (ALND) can be safely omitted in select patients, according to a research presented at the 2015 San Antonio Breast Cancer Symposium.
The use of sentinel lymph node biopsy (SLNB) alone for care for axillary management in breast cancer patients with negative nodes is on the increase, according to study data presented at the 2015 San Antonio Breast Cancer Symposium.
New study findings presented at SABCS 2015 suggest that BRCAT431 promotes tamoxifen resistance, thereby increasing the clinical risk of recurrence and metastases in breast cancer.
A novel genetic driver analysis of matched breast cancer primary tumors and multiorgan metastases suggests that most genetic drivers in a single tumor are based on DNA copy number variants (CNV), are established early, and are maintained in metastases. These findings were presented at the 2015 San Antonio Breast Cancer Symposium.
Ten-year Overall Survival Is Higher After Breast-conserving Therapy Compared With Mastectomy in Early Stage Breast Cancer
Breast-conserving surgery with radiation therapy (BCT) demonstrated improved 10-year overall survival in patients with early stage breast cancer compared with mastectomy without radiation therapy, according to data presented at the 2015 San Antonio Breast Cancer Symposium.
EPclin Score Provides More Prognostic Information for Residual Distant Recurrence in ER+/HER2- Breast Cancer
EndoPredict (EP) provided superior information to the Oncotype DX recurrence score (RS) for distant recurrence (DR) in overall, N+, and N- patient populations, and also pinpointed a low-risk patient group who may not need chemotherapy.
Synthetic 2D Mammography Is Cost Effective and Reduces X-ray Exposure in Breast Cancer Screening Mammography
Use of a synthetic 2D mammogram, instead of a standard 2d film, may offer breast cancer patients the benefits of 2D/3D screening combinations at a reduced radiation exposure level.
Adding Carboplatin to Neoadjuvant Therapy for Triple-negative Early Breast Cancer Improves Disease-free Survival
Carboplatin added to anthracycline/taxane-based neoadjuvant chemotherapy significantly improved pathological complete response rates in patients with triple-negative breast cancer in two large phase IIb studies: GeparSixto and CALGB 40603. Researchers reported on disease-free survival for GeparSixto after median 35 months of observation at the 2015 San Antonio Breast Cancer Symposium.
Premenopausal Patients With High-risk Luminal A Breast Cancer Get No Benefit From Adjuvant Chemotherapy
Premenopausal women with luminal A subtype breast cancer had comparable 10-year disease-free survival rates regardless of whether they received adjuvant chemotherapy, according to data presented at the 2015 San Antonio Breast Cancer Symposium.
Avelumab has an acceptable safety profile in patients with metastatic breast cancer and demonstrated signs of greater clinical activity in specific subsets of patients.
Idelalisib With Bendamustine and Rituximab Superior to Bendamustine and Rituximab alone for Relapsed/Refractory CLL
For patients with relapsed/refractory CLL, the addition of idelalisib to bendamustine and rituximab can prove more beneficial than the latter two drugs alone, recent study data suggest.
A recent study examined the direct and indirect costs for patients with relapsed or refractory multiple myeloma.
Results of a phase 3 randomized trial support high intensity conditioning with myeloablative regimens prior to allogeneic stem cell transplantation as standard of care for patients with acute myeloid leukemia.
Treatment with venetoclax monotherapy may be a viable option for some high-risk patients with relapsed/refractory chronic lymphocytic leukemia.
Overall survival rates for Medicare beneficiaries with myelodysplastic syndrome (MDS) showed little difference related to disease-related costs, according to data presented at the 2015 ASH Annual Meeting in Florida.
A PET-guided approach may reduce the need for additional radiotherapy in some patients with advanced classical Hodgkin lymphoma.
In the first clinical trial of an anti-B-cell maturation antigen chimeric antigen receptor (CAR-BCMA), a strong anti-myeloma response was observed.
The high cost of for first-line oral targeted therapies for chronic lymphocytic leukemia needs to be addressed, based on model data examining CLL prevalence and patient affordability.
PET deemed safe for use after two cycles of BEACOPPesc chemotherapy for advanced stage Hodgkin lymphoma, according to a recent study.
Immunophenotypic expression profiles can provide a tool to discriminate cohorts of young patients with acute myeloid leukemia (AML) that have a high relapse probability.
Treatment benefit can be predicted through genotyping from blood plasma, according to several studies presented at ELCC 2016; however, plasma tests are unlikely to fully replace tissue biopsies.
A potential link between long-term oral treatment with nucleos(t)ide analogues for chronic hepatitis B virus (HBV) and an increased risk of colorectal and cervical cancers was demonstrated.
Glioblastoma tumors were successfully infiltrated by investigational CAR therapy with an acceptable safety profile.
A nurse-facilitated oral chemotherapy care model has improved delivery times, patient satisfaction, and co-pay support at a Connecticut cancer hospital.
Follow-up telephone calls and clinician assessment may be an effective strategy to identify early which patients require support with adhering to oral cancer therapy.
A nurse-managed precision cancer treatment education resource center may improve information dissemination about genomic health and targeted therapy.
Instituting a Chemotherapy Safety Committee and developing an administration process successfully standardized the inpatient oral chemotherapy administration process.
A formal nursing practice was developed to promote patient safety and adherence with oral chemotherapy.
Implementation of the Massey Bedside Swallowing Screen and strict oral care regimens in high-risk patients reduced the rate of hospital-acquired pneumonia (HAP) at an oncology treatment center.
A central venous catheter self-management education program is an effective nursing intervention to promote long-term self-management of a CVC for discharged patients with cancer.
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Navigator-specific Interventions and Multidisciplinary Care Team Collaboration Improves Care and Outcomes for Patients with GI Cancers
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Research Identifies Underlying Mechanism of Chemotherapy-Induced Peripheral Neuropathy
- Oncology Nurses Should Be Aware of Complexities of Neuroendocrine Tumors
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Acupuncture Improves Management of Hot Flashes, Quality of Life in Breast Cancer
- Higher Vitamin D Levels Lower Risk of Cancer in Women
- Getting Started: Implementation of an Oncology Navigation Program That Meets Community Needs
- Beyond Treatment: Anticipating the Late Effects of Cancer Treatment in Survivors
- Initiating Palliative Care in the Emergency Department
- Blood Plasma Genotyping Predictive of Treatment Benefit in NSCLC
- Chronic HBV Treatment Linked to Increased Rates of Colorectal and Cervical Cancer
- Phase 1 Study Results Show CAR T-cell Therapy Promising in Solid Brain Tumors
- A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|